Bank of America Securities Sticks to Their Buy Rating for Danaher (DHR)
Bank of America Securities analyst Michael Ryskin maintained a Buy rating on Danaher yesterday and set a price target of $270.00.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ryskin covers the Healthcare sector, focusing on stocks such as Illumina, Zoetis, and Elanco Animal Health. According to TipRanks, Ryskin has an average return of 2.9% and a 53.61% success rate on recommended stocks.
In addition to Bank of America Securities, Danaher also received a Buy from TipRanks – PerPlexity’s PerPlexity Medical – Diagnostics and Research in a report issued today. However, on the same day, TipRanks – xAI reiterated a Hold rating on Danaher (NYSE: DHR).
Based on Danaher’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $6.84 billion and a net profit of $1.2 billion. In comparison, last year the company earned a revenue of $6.54 billion and had a net profit of $1.09 billion
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHR in relation to earlier this year. Most recently, in November 2025, Mitchell Rales, the Chairman of Exec. Committee of DHR sold 40,625.00 shares for a total of $9,359,066.67.
Read More on DHR:
